Baranco
2
11M
2
- Areas of investment
Summary
Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund. Among the most successful fund investment fields, there are Biotechnology, Neuroscience. Among the most popular portfolio startups of the fund, we may highlight Sky Medical Technology.
The typical case for the fund is to invest in rounds with 5 participants. Despite the Baranco, startups are often financed by Juno Capital Partners, Spark Ventures, Nigel Rudd. The meaningful sponsors for the fund in investment in the same round are Revera Home Health Business, Nissha Co., Ltd., Juno Capital Partners. In the next rounds fund is usually obtained by Barvest Ventures.
The top activity for fund was in 2017. The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 10 - 50 millions dollars.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Investments by industry
- Neuroscience (1)
- Health Care (1)
- Biotechnology (1)
- Medical (1)
- Medical Device (1)
- Investments by region
-
- United Kingdom (1)
- United States (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Xenocor | 18 Apr 2023 | Medical Device | Early Stage Venture | 10M | Salt Lake City, Utah, United States |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.